XML 41 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue from Significant Partners
Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:
Year ended December 31,
2022
2021(a)
2020(a)
Partner A45%47%51%
Partner B16%12%17%
Partner C<10%<10%<10%
(a) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Schedule of Commercial License Rights
As of December 31, 2022 and 2021, commercial license and other economic rights consist of the following (in thousands):
December 31, 2022December 31, 2021
Gross
Adjustments(1)
NetGross
Adjustments(2)
Net
Aziyo and CorMatrix$17,696 $(9,538)$8,158 $17,696 $(9,461)$8,235 
Selexis and Dianomi10,602 (8,578)2,024 10,602 (8,727)1,875 
     Total$28,298 $(18,116)$10,182 $28,298 $(18,188)$10,110 

(1) Amounts represent accumulated amortization to principal of $11.6 million and credit loss adjustments of $6.5 million as of December 31, 2022.
(2) Amounts represent accumulated amortization to principal of $11.7 million and credit loss adjustments of $6.5 million as of December 31, 2021.
Schedule of Disaggregation of Revenue
Royalty revenue for 2022, 2021 and 2020 for continuing operations are reported as below (in thousands):
Year ended December 31,
202220212020
Kyprolis$30,116 $27,472 $25,164 
Evomela10,197 10,079 6,377 
Teriparatide injection 15,785 5,260 — 
Rylaze 8,796 2,420 — 
Other7,633 3,696 2,255 
$72,527 $48,927 $33,796 

The following table represents disaggregation of Captisol and contract revenue for continuing operations (in thousands):
Year ended December 31,
202220212020
Captisol
     Captisol - Core$16,429 $23,423 $24,566 
     Captisol - COVID(a)
88,066 140,827 85,393 
$104,495 $164,250 $109,959 
Contract
     Service Revenue$1,117 $3,737 $9,330 
     License Fees2,849 634 119 
     Milestone9,150 17,584 5,217 
     Other6,107 6,412 5,141 
$19,223 $28,367 $19,807 
(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.
Schedule of Computation of Basic and Diluted Net Income (Loss) per Share The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):
Year Ended December 31,
 202220212020
Weighted average shares outstanding:16,868 16,630 16,185 
Dilutive potential common shares:
   Restricted stock— 96 56 
   Stock options— 520 584 
Shares used to compute diluted income per share16,868 17,246 16,825 
Potentially dilutive shares excluded from calculation due to anti-dilutive effect6,241 4,793 8,458